Diabetes Care Devices Market

Market Overview

The global Diabetes Care Devices Market was valued at approximately USD 28.5 billion in 2024 and is projected to reach USD 47.2 billion by 2033, growing at a CAGR of 5.9% during the forecast period (2025–2033).

Diabetes management devices are utilized by patients living with diabetes to monitor blood sugar levels and deliver insulin to patients as part of their care. The diabetes management devices defined fall into categories: blood glucose meters, test strips, continuous glucose monitor (CGM) devices, insulin pumps, and insulin pens. These devices facilitate the management of both Type 1 and Type 2 diabetes by providing important information on glucose levels real-time (with CGMs) and delivering the precision of the preferred insulin delivery mechanism to patients. The large increase of people living with diabetes around the world, especially due to an aging population, sedentary lifestyle, and dietary factors, are expected to be the major driving factors for market demand.

Advances in technology, such as smart CGMs, insulin delivery systems integrated with mobile devices, and data analytics using AI, provide ease of use and convenience are boosting the acceptance and demand for diabetes management devices by patients. Additionally, awareness-building of disease burden population, government program initiatives on diabetes management, and improved access to physician and medical care provided where diabetes is not seen by all physicians, in developing economies is expected to grow the market.

Market Dynamics

Market Drivers

Rising Global Prevalence of Diabetes and Pre-Diabetes Conditions

The diabetes epidemic is significantly impacting the expansion of the diabetes care devices market. Type 2 diabetes, in particular, is experiencing explosive growth. Based on data from the International Diabetes Federation (IDF), while there were 537 million adults (20–79 years) living with diabetes in 2021, that number is expected to increase to 643 million by 2030 and 783 million by 2045.

Many individuals in populations all around the world are living with undiagnosed or pre-diabetic conditions; highlighting the need for diagnosis and tracking. Urbanization, sedentary lifestyles, unhealthy eating habits, and increasing rates of obesity are all significant factors driving the prevalence of diabetes. For example, the CDC reports that more than 96 million U.S.-adults, or more than 1 in 3, have pre-diabetes. Many of these individuals will eventually develop Type 2 diabetes over the next five years if there is no change in lifestyle.

The growth of the diabetic and pre-diabetic populations has created a strong demand for blood glucose monitoring devices including continuous glucose monitors (CGMs, also referred to as flash glucose monitoring devices) and glucometers; that help individuals with all forms of diabetes to control their blood sugar levels. As awareness continues to grow for early diagnoses and tight glycemic controls, there is also a push for habitually screening and monitoring across their governments and health organizations. This drives further adoption of devices.

Government Initiatives, Growing Healthcare Spending, and Aging Population

Advancements in device technology have significantly changed the diabetes care market, improving monitoring, insulin delivery, accuracy, invasiveness, and ease of use. Continuous glucose monitoring (CGM) systems have advanced through the use of real-time transmissions, smartphone connections, and wearables.

Some of the market leaders such as Dexcom, Abbott, and Medtronic have developed sophisticated, next-generation CGM products. Products such as the Dexcom G7 and Abbott’s FreeStyle Libre 3 are sophisticated but small, with a painless insertion, and provide users with real-time glucose data, as well as alerts, on their smartphones! Insulin delivery devices have also been subject to major innovations. Smart insulin pens and patch pumps have provided better dosing accuracy, and have made it easy for patients to monitor their insulin intake digitally.

Novo Nordisk has created connected insulin pens that help patients manage their personalized insulin dosing through mobile apps. The Insulet Omnipod 5 insulin pump can also deliver a user’s insulin automatically, as the pump communicates with the patient’s CGM and makes dosing decisions without patient input. These innovations have provided patients the opportunity for increased convenience and compliance, but also have shown, clinically, that they reduce hypoglycemic episodes, the burden of diabetes care and long term complications, which have an impact on patient outcomes.

With clinical data supporting the efficacy of these devices, and the related regulatory approvals, the demand for advanced technology is going to continue to rise quickly. At the same time, increasing global healthcare expenditures are making space for innovation and adoption. According to the World Bank, global health expenditures reached USD 9 trillion in 2022, which allowed for upgrades to infrastructure, improved diagnostics, and purchases of new devices.              

In addition, aging populations globally are at increased risk of developing Type 2 diabetes. The United Nations estimated that the number of individuals aged 65 years or older will reach over 1.5 billion by 2050, which will double in the next 20 years. Older adults are at an increased risk for complication, and they tend to have more frequent injections or glucose monitoring, generating even more demand for user-friendly and sustainable products to manage diabetes.

Market Restraints

High Cost of Advanced Diabetes Devices and Limited Reimbursement in Developing Economies

One of the major challenges in the diabetes care devices market is the high cost associated with advanced technologies like continuous glucose monitoring (CGM) systems and insulin pumps. CGM systems and insulin pumps improve glycemic management and allow the patient to enjoy a higher degree of convenience; however, their initial costs and ongoing costs (e.g., device sensor replacements, infusion set costs, transmitters) prohibit many individuals from accessing these devices.

This situation is especially true in low- and medium-income countries. For example, a CGM like the Dexcom G6 can be easily easily more than USD 300–400 monthly cost when taking into consideration the ongoing cost of the sensors and transmitters. Insulin pumps can be valued from USD 4,000–6,000 on initial purchase with ongoing supply costs.

This cost barrier will certainly limit uptake in countries where a population has little insurance and no public health rationale for reimbursement. On top of this, across many developing or non-developed localities in Asia, Latin America, and Africa, the healthcare systems lack the infrastructure or budget to subsidise these devices, and direct health expenses remain in the thousands of dollars for the patient at current conversions.

In many developed countries where health policy reimbursement does exist, remuneration is very often confined to a sub-group of patients (e.g., children with Type 1 diabetes), therefore, hundreds of thousands of patients and members of population are left behind in terms of being able to access these life-enhancing technologies.

Segmental Analysis

The Diabetes Care Devices Market is segmented by product type and end-user. Each segment plays a critical role in improving glycemic control, patient self-management, and treatment personalization.

By Product Type

This segment held the highest market share at 58.7% in 2024 due to the immense requirement for regular glucose testing for both Type 1 and Type 2 diabetes patient groups. The Self-Monitoring Blood Glucose (SMBG) sub-segment is a larger share of the market by volume because of the high volume of test strips sold as well as the low pricing of glucometers in low-income and middle-income countries.

The Continuous Glucose Monitoring (CGM) sub-segment will grow the fastest in terms of CAGR as the demand rises for real-time availability and access to glucose monitoring, primarily driven by insulin-dependent diabetic patients. Other factors in the increased prevalence of CGM include devices like Dexcom, G7, FreeStyle Libre 3 and Medtronic Guardian Connect which are gaining acceptance as they reduce hypoglycemic events, increase time-in-range and are compatible with insulin delivery systems and mobile health applications.

Insulin delivery devices were the second-most significant segment accounting for 36.5% share in 2024 driven by the increase in the number of patients that require insulin delivery and the improvement in delivery devices. Insulin pens are the most commonly used device in this segment due to user-friendliness, accuracy, and training limitations compared to syringes.

On the other hand, insulin pumps are also rapidly growing their use, mainly in pediatric and Type 1 patients, with new products driving market growth, such as automated insulin delivery systems (AID) and patch pumps, including Omnipod 5 and Tandem t:slim X2 products. Yet, costs and outside of the U.S., reimbursement are obviously barriers to utilization. Insulin syringes and jet injectors are even smaller, though, in part, not advancing as rapidly due to new and innovative user-friendly, smart replacement devices and products.

By End-User

In 2024, hospitals dominated the diabetes care devices market with a market share of 44.1% due to their role in acute diabetes management, in-patient care, and administering therapeutic devices. Hospitals are also leading users of advanced insulin delivery systems especially with critical care or newly diagnosed patients. Institutional procurement also means that CGMs have wider availability for patients that are admitted to hospitals and allows for more accurate monitoring during hospital care.

The home care segment will see the largest annual growth rate during the forecast period. This is due to an increase in patient preference for at-home glucose monitoring and at-home insulin administration, along with innovations in connected and portable devices. The availability of CGMs that adapt to smartphones and new bluetooth connected insulin pens allows patients to self-manage their diabetes, especially for elderly and pediatric patients. The diagnostic centers took a moderate share of the market in 2024. They perform integral tasks with regard to diabetes screening, monitoring, and lab based HbA1C testing.

Their growth will be slower since they are being replaced by self-monitoring and digital health platforms or solutions that, in some cases, offer individuals the potential to minimize their clinical visits. Retail pharmacies are beginning to engage related to device distribution, patient education and, in some areas of the world, basic glucose screening.

Regional Analysis

North America

North America is expected to hold the largest market share of 41.3% in 2024 driven by the high prevalence of diabetes, mature and extensive healthcare systems, and swift adoption of newer diabetes technologies. The participating country the U.S. has over 38 million people with diabetes in 2023 (CDC).

The market has been able to grow through the presence of leading manufacturers such as Dexcom, Medtronic, Abbott, and Insulet, along with favorable reimbursement policies for CGMs and insulin pumps that have greatly facilitated their use in patients with diabetes. The region also has a higher levels of digital health literacy and patient awareness, which is leading to it being the primary testing ground for the latest technologies to hit the market. 

Europe

Europe continues to represent significant regional markets with high-device penetration in particular countries like Germany, the UK, France, and the Netherlands. According to the International Diabetes Federation, Europe had over 61 million adults with diabetes in 2023.

Currently, the aging population among a nation with government supported insurance and reimbursement policies being favorable towards CGMs and a greater acceptance of insulin pens should allow Europe to grow. Countries such as Sweden and Germany are more resembling by embracing the technologies of CGM and insulin pumps. Additionally, the EU’s push towards investment in digital health strategy is fostering a use of connected diabetes care devices enriched with AI components.

Asia-Pacific

The Asia-Pacific region is expected to grow at a fast CAGR of 8.5% during the forecast period (2025–2033) due to a rapidly increasing diabetic population, rising healthcare expenditure, and advancements in technology access to medical technology amongst China, India, and Japan.

China alone has over 140 million people with diabetes (the largest population in the world), and it is worth noting that these changes are resulting from rising urbanization, changing lifestyles, as well as growing awareness surrounding early diagnosis will increase demand for blood glucose monitors and insulin pens. In addition, governmental initiatives such as India’s Ayushman Bharat initiative as well as China digitizing their healthcare systems will lead to further permeation of these devices into emerging markets.

Latin America and Middle East & Africa

Latin America and the MEA regions are also experiencing moderate development due to an improving healthcare system and patients and governments looking to address the inherent burden that diabetes has. For instance, Brazil, Mexico, South Africa, and Saudi Arabia are countries focusing on building primary care infrastructure with diabetes-related screening improvements.

Despite this, obstacles such as (1) limited reimbursement, (2) high out-of-pocket spending for healthcare, and (3) inadequate awareness surrounding diabetes especially in rural areas is limiting the spread of advanced devices such as continuous glucose monitors (CGM) and insulin pumps. There are further possibilities for growth within these regions through potential partnerships and investments in healthcare system infrastructure.

Recent Development

1. April 2025 – Medtronic advances partnership with Abbott CGM, submitting FDA application for an interoperable insulin pump as part of the Simplera ecosystem.
2. April 2025 – ATTD 2025 highlights announced upcoming devices: Abbott’s glucose‑ketone CMG, Dexcom G7 15‑Day Sensor, Medtronic Simplera CGM, Eversense 365 + pump partner, Tandem’s tubeless Mobi pump, and Sequel twiist AID system.